New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
09:13 EDTONCYOncolytics Biotech reports FY12 EPS (C$0.48), consensus (43c)
Reports FY12 Research and development expensed C$31.4M.
News For ONCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
06:41 EDTONCYOncolytics announces completion of enrollment in Phase II Reolysin study
Oncolytics Biotech announced that enrollment has been completed in a randomized Phase II study of Reolysin in patients with recurrent or metastatic castration resistant prostate cancer. The trial is being sponsored and conducted by the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario. The study is an open-label, randomized, non-blinded, Phase II clinical study of Reolysin given in combination with docetaxel versus docetaxel alone. Approximately 40 response evaluable patients were enrolled in each arm. Although accrual is complete, patient follow-up will continue until planned analyses have been conducted.
06:34 EDTONCYOncolytics completes enrollment in Phase II study of Reolysin
Subscribe for More Information
September 25, 2015
06:32 EDTONCYOncolytics collaborators present data from clinical study in multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use